Merck-NewLink Ebola vaccine trial resumes at lower dose: Geneva hospital

GENEVA (Reuters) - The clinical trial of an Ebola vaccine developed by Merck and NewLink resumed on Monday at a lower dose after a pause to assess complaints of joint pains in some volunteers, the University of Geneva hospital said. An Ebola outbreak, the worst on record of the highly infectious hemorrhagic fever, has killed over 7,900 people over the past year, with more than 20,000 cases recorded mostly in Guinea, Sierra Leone and Liberia, according to the World Health Organization (WHO). The virus is still spreading in West Africa, especially in Sierra Leone. ...



via Health News Headlines - Yahoo News http://ift.tt/1HySIIk